Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).
J Dermatolog Treat
December 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Article Synopsis
- * In a study with 85 adults, 49.4% of patients showed at least a 90% improvement in eczema severity, while 61.2% had a favorable assessment from doctors.
- * No major safety issues were reported, and naïve patients (those who hadn't previously tried treatment) had better outcomes than those who had failed another medication, highlighting its effectiveness in real-world settings.
Fungi-sensitized individuals have unique profiles where Alt a 1 dominates promoting response to grass, ragweed and cat allergens.
Front Allergy
August 2024
Department of Allergology, SI Institute of Otolaryngology n.a. Prof.O.S. Kolomiychenko of NAMS of Ukraine, Kyiv, Ukraine.
Introduction: The aim of our work was to determine comprehensively the sensitization profile of patients hypersensitive to fungal allergenic components in the Ukrainian population, identifying features of their co-sensitization to allergens of other groups and establishing potential relationships between causative allergens and their ability to provoke this hypersensitivity.
Methods: A set of programs was developed using Python and R programming languages, implementing the K-means++ clustering method. Bayesian networks were constructed based on the created clusters, allowing for the assessment of the probabilistic interplay of allergen molecules in the sensitization process of patients.
AWMF mold guideline "Medical clinical diagnostics for indoor mold exposure" - Update 2023 AWMF Register No. 161/001.
Allergol Select
May 2024
Laboratory Dr. Wisplinghoff.
Article Synopsis
- This text lacks any provided content or specific information.
- Without details, it is impossible to summarize or draw key points.
- For a meaningful synopsis, additional context or a defined topic is needed.
Cross-reactivity among and between macrolides, lincosamides, and streptogramins: Study on the French pharmacovigilance database.
Fundam Clin Pharmacol
October 2024
Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, Angers, France.
Background: Hypersensitivity reactions (HSR) are reported for the macrolides, lincosamides, and streptogramins (MLS) antibiotic family. Data about cross-reactivity among and between MLS remain scarce or controversial.
Objectives: The aim of this study was to provide an overview of hypersensitivity cross-reactions among MLSs based on data extracted from the French National Pharmacovigilance Database (FPVD).
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
Dermatol Ther (Heidelb)
April 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Article Synopsis
- - Several Janus kinase inhibitors (JAKi), like abrocitinib, baricitinib, and upadacitinib, are now approved for treating severe atopic dermatitis (AD), but there are concerns about their long-term safety and real-world application.
- - A group of twelve Italian dermatologists conducted a Delphi consensus to review the current knowledge and establish clinical recommendations for the use of JAKi based on their efficacy and safety.
- - The consensus reached agreement on key areas including the role of JAKi in therapy, their effectiveness across different patient types, and management strategies, highlighting the importance of tailored follow-up for optimal patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!